<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304589</url>
  </required_header>
  <id_info>
    <org_study_id>CSBrown SAV-MD-18</org_study_id>
    <nct_id>NCT01304589</nct_id>
  </id_info>
  <brief_title>Savella in Treatment for Provoked Vestibulodynia</brief_title>
  <official_title>An Open Label Trial of Milnacipran in the Treatment of Women With Provoked Vestibulodynia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine the efficacy of milnacipran in reducing pain in
      women with provoked vestibulodynia (PVD), a centrally mediated pain syndrome similar to
      fibromyalgia, that is characterized by severe pain in the vestibule (outer vagina). The
      investigators will also determine whether associated symptoms in PVD, including psychological
      distress, impairment of sexual function, physical function, and quality of life, are
      correlated with a reduction in vulvar pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 18-week, open-label, flexible-dose &quot;proof of concept&quot; trial where women with a
      diagnosis of vestibulodynia will be evaluated at baseline for eligibility. Eligible patients
      will be openly treated with 200 mg/d milnacipran (or the maximum tolerated dose) for a total
      of 12 weeks. The study design involves 4 phases: screening and washout, baseline assessment,
      dose escalation, and stable-dose phase (Figure 1). After completing a 2-week washout of
      prohibited medications, patients will enter a 2-week baseline period, where they will be
      trained in the use of daily diaries and the tampon test, and baseline safety and efficacy
      data will be recorded. Patients who continue to meet the eligibility criteria at the end of
      the baseline period will begin a 6-week period of dose escalation. All patients will be
      scheduled to receive a total of 12 weeks of stable dose treatment after the 6-week
      dose-escalation period for a total of 18 weeks of drug exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Rating Index</measure>
    <time_frame>18 weeks</time_frame>
    <description>The primary outcome measure will be pain ratings on the Pain Rating Index (PRI) of the short-form McGill Pain Questionnaire (SF-MPQ), which consists of 15 representative words from the sensory (n = 11) and affective (N = 4) categories of the standard, long-form (LF-MPQ). On the PRI, each descriptor is ranked by the patient on an intensity scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. Total score - &quot;0&quot; equals no pain to &quot;45&quot; equals severe pain. The paired t-test was used to compare the PRI score at baseline and at 18 weeks or to further clarify, pre-treatment versus post-treatment comparison.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tampon Pain</measure>
    <time_frame>18 weeks</time_frame>
    <description>Subjects completed a &quot;tampon insertion pain&quot; test once a week in their daily diary. The values were averaged and compared pre-treatment versus post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coital Pain</measure>
    <time_frame>18 weeks</time_frame>
    <description>Intercourse pain is measured by completing a daily diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour Vulvar Pain</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measures average vulvar pain over 24-hours on daily diary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Vestibulodynia</condition>
  <condition>Vulvodynia</condition>
  <arm_group>
    <arm_group_label>Milnacipran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose)for 12 weeks - total treatment period is 18 weeks</description>
    <arm_group_label>Milnacipran</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women between 18-54 years of age,

          2. 'Friedrich's Criteria' must be met (report greater than six continuous months of
             vulvar symptoms including insertional dyspareunia or pain to touch, demonstrate on
             physical exam moderate to severe tenderness to light touch, localized to the vulvar
             vestibule [positive Cotton Swab Test] and demonstration of variable degrees of
             erythema of the vestibule),

          3. an average pain level of &quot;4&quot; or greater on the 10-point tampon test and/or an average
             pain level of &quot;4&quot; or greater on the sexual intercourse pain scale(0 = no pain at all;
             10 = worse pain ever) during the 2-week screening period(see Study Parameters
             Section), and

          4. willing to use two forms of contraception during the study.

        Exclusion Criteria:

          1. other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, and
             atrophic vaginitis (presence of a maturation index),

          2. previous vestibulectomy,

          3. active vaginal infection,

          4. neuropathology, including seizure disorder or syncopal episodes,

          5. pregnancy or at risk for pregnancy and not using a reliable birth control method for
             at least 3 months prior to entering the study,

          6. breastfeeding,

          7. major medical illness including chronic liver disease/hepatic impairment, renal
             impairment, narrow-angle glaucoma, or uncontrolled hypertension,

          8. major psychiatric illness including substance abuse,

          9. multiple allergies (greater than three drugs or environmental agents),

         10. use of centrally-acting agents, including monoamine oxidase inhibitors,
             benzodiazepines, opiates, muscle relaxants, and antidepressants within 2 weeks of
             randomization and during the study, and

         11. use of topical lidocaine, within 2 weeks of randomization and during the study, as it
             has shown to be an effective treatment in some women, while worsening symptoms in
             others. Subjects will be permitted to take acetaminophen, aspirin, or a nonsteroidal
             anti-inflammatory drug as rescue medication. They will be provided with a list of
             allowable escape medications and those which would constitute a protocol deviation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candace S Brown, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Specialists, PLLC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <results_first_submitted>December 29, 2013</results_first_submitted>
  <results_first_submitted_qc>February 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2014</results_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tennessee</investigator_affiliation>
    <investigator_full_name>Candace Brown, MSN, Pharm.D.</investigator_full_name>
    <investigator_title>Professor, Departments of Clinical Pharmacy, Psychiatry and Obstetrics/Gynecology</investigator_title>
  </responsible_party>
  <keyword>provoked vestibulodynia</keyword>
  <keyword>vulvodynia</keyword>
  <keyword>PVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvodynia</mesh_term>
    <mesh_term>Vulvar Vestibulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Milnacipran</title>
          <description>Milnacipran: 6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose)for 12 weeks - total treatment period is 18 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Milnacipram</title>
          <description>Open-label study of milnacipram. 50 to 200 milligrams orally per day. Tablets were taken in the morning during an 18-week clinical trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Rating Index</title>
          <description>The Pain Rating Index is a component of the McGill Pain Questionnaire which measures sensory and affective components of pain. &quot;0&quot; equals no pain to &quot;45&quot; equals severe pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tampon test</title>
          <description>&quot;0&quot; equals no pain with tampon insertion to &quot;10&quot; equals worse pain imaginable with tampon insertion.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.14" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>coital pain</title>
          <description>&quot;0&quot; equals no pain with intercourse to &quot;10&quot; equals worse imaginable pain with intercourse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.94" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour vulvar pain</title>
          <description>&quot;0&quot; equals no vulvar pain within the last 24 hours to &quot;10&quot; equals worse imaginable vulvar pain within the last 24 hours.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.09" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Rating Index</title>
        <description>The primary outcome measure will be pain ratings on the Pain Rating Index (PRI) of the short-form McGill Pain Questionnaire (SF-MPQ), which consists of 15 representative words from the sensory (n = 11) and affective (N = 4) categories of the standard, long-form (LF-MPQ). On the PRI, each descriptor is ranked by the patient on an intensity scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. Total score - &quot;0&quot; equals no pain to &quot;45&quot; equals severe pain. The paired t-test was used to compare the PRI score at baseline and at 18 weeks or to further clarify, pre-treatment versus post-treatment comparison.</description>
        <time_frame>18 weeks</time_frame>
        <population>22 subjects were eligible and received study medication. Analysis population included all 22 eligible subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipram</title>
            <description>open-label study</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Rating Index</title>
          <description>The primary outcome measure will be pain ratings on the Pain Rating Index (PRI) of the short-form McGill Pain Questionnaire (SF-MPQ), which consists of 15 representative words from the sensory (n = 11) and affective (N = 4) categories of the standard, long-form (LF-MPQ). On the PRI, each descriptor is ranked by the patient on an intensity scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. Total score - &quot;0&quot; equals no pain to &quot;45&quot; equals severe pain. The paired t-test was used to compare the PRI score at baseline and at 18 weeks or to further clarify, pre-treatment versus post-treatment comparison.</description>
          <population>22 subjects were eligible and received study medication. Analysis population included all 22 eligible subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.001</p_value>
            <p_value_desc>A paired T-Test was calculated assuming a standard difference (d) between the 4 paired outcomes for pain of 0.60 (moderate effect size), a SD of 1 for each outcome variable and a correlation of 0.50 between each paired variable.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tampon Pain</title>
        <description>Subjects completed a &quot;tampon insertion pain&quot; test once a week in their daily diary. The values were averaged and compared pre-treatment versus post-treatment.</description>
        <time_frame>18 weeks</time_frame>
        <population>22 subjects were eligible and received study medication. Analysis population includes all 22 eligible subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Milnacipran: 6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose)for 12 weeks - total treatment period is 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tampon Pain</title>
          <description>Subjects completed a &quot;tampon insertion pain&quot; test once a week in their daily diary. The values were averaged and compared pre-treatment versus post-treatment.</description>
          <population>22 subjects were eligible and received study medication. Analysis population includes all 22 eligible subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.003</p_value>
            <p_value_desc>A paired T-Test was calculated assuming a standard difference (d) between the 4 paired outcomes for pain of 0.60 (moderate effect size), a SD of 1 for each outcome variable and a correlation of 0.50 between each paired variable.</p_value_desc>
            <method>paired T-test</method>
            <method_desc>Subjects completed a &quot;tampon insertion pain&quot; test once a week. The values were averaged and compared pre-treatment versus post-treatment.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coital Pain</title>
        <description>Intercourse pain is measured by completing a daily diary</description>
        <time_frame>18 weeks</time_frame>
        <population>22 subjects were assigned to study medication with 18 of the 22 subjects completing all of the study visits. Analysis population includes the 18 eligible subjects who completed all of the study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipram</title>
            <description>Crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Coital Pain</title>
          <description>Intercourse pain is measured by completing a daily diary</description>
          <population>22 subjects were assigned to study medication with 18 of the 22 subjects completing all of the study visits. Analysis population includes the 18 eligible subjects who completed all of the study visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.001</p_value>
            <p_value_desc>A paired T-Test was calculated assuming a standard difference (d) between the 4 paired outcomes for pain of 0.60 (moderate effect size), a SD of 1 for each outcome variable and a correlation of 0.50 between each paired variable.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Vulvar Pain</title>
        <description>Measures average vulvar pain over 24-hours on daily diary</description>
        <time_frame>18 weeks</time_frame>
        <population>22 subjects were randomized to study medication with 18 of the 22 subjects completing all of the study visits. Analysis population includes all 18 eligible subjects who completed all of the study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipram</title>
            <description>Crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Vulvar Pain</title>
          <description>Measures average vulvar pain over 24-hours on daily diary</description>
          <population>22 subjects were randomized to study medication with 18 of the 22 subjects completing all of the study visits. Analysis population includes all 18 eligible subjects who completed all of the study visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>A paired T-Test was calculated assuming a standard difference (d) between the 4 paired outcomes for pain of 0.60 (moderate effect size), a SD of 1 for each outcome variable and a correlation of 0.50 between each paired variable.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Milnacipram</title>
          <description>Crossover study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Candace Brown</name_or_title>
      <organization>University of Tennessee Health Science Center</organization>
      <phone>901-412-4341</phone>
      <email>csbrown@uthsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

